Therapeutic Proteins Global Market Report 2024

The therapeutic proteins market size has grown rapidly in recent years. It will grow from $140.96 billion in 2023 to $158.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The expansion observed in the historical period can be credited to progress in protein engineering, the extension into chronic diseases, the emergence of immunotherapy, the evolution of recombinant DNA technology, and the introduction of targeted cancer therapies.

The therapeutic proteins market size is expected to see rapid growth in the next few years. It will grow to $257.4 billion in 2028 at a compound annual growth rate (CAGR) of 12.9%. The anticipated growth in the forecast period can be ascribed to regulatory adaptations, advancements in delivery systems, integration of gene editing, development of biobetters, and the evolution of immunotherapy. Key trends expected in the forecast period encompass enhancements in regulatory frameworks, superior delivery systems, advancements in biotechnology, the rise of personalized medicine, and the dominance of monoclonal antibodies.

Technological advancements in protein-based drug development are a driving force behind the therapeutic proteins market. Unlike as chemical synthesis, therapeutic proteins necessitate production through genetic engineering and recombinant DNA technology within living cells or organisms. Various protein-engineering platform technologies, such as glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation, play a pivotal role in enhancing production yield, product purity, circulating half-life, targeting, and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, and recombinant human coagulation factor IX are examples of therapeutic protein drugs developed using protein engineering technologies and FDA-approved in the past five years.

The future growth of the therapeutic protein market is expected to be fueled by the increasing prevalence of chronic diseases, notably diabetes. Chronic diseases, persisting for a year or more and requiring ongoing medical care, are on the rise. Diabetes, characterized by insufficient insulin production or improper insulin usage, is managed with protein therapeutics such as insulin and GLP-1 receptor agonists. These proteins regulate blood sugar levels by stimulating insulin release in response to elevated glucose and reducing the production of glucagon. The International Diabetes Federation reported in December 2021 that diabetes affected 537 million adults aged 20–79 in 2021, with projections reaching 643 million by 2030 and 783 million by 2045. Hence, the increasing prevalence of chronic diseases, particularly diabetes, is a significant driver for the therapeutic protein market.

The growth of the therapeutic proteins market is expected to face a slowdown due to the increasing presence of biosimilar drugs on the global market. The expiration of patents for therapeutic proteins, including monoclonal antibodies, opens the door for biosimilars to enter the market. For instance, in October 2022, Amneal Pharmaceuticals, Inc., a US-based generics and specialty pharmaceutical company, introduced ALYMSY® (bevacizumab-maly) in the United States. While these biosimilars offer cost-effective alternatives to original biologics, their entry into the market leads to a decline in revenue and sales for the therapeutic proteins market.

The protein therapeutic segment is experiencing a surge in approvals for monoclonal antibody drugs. Monoclonal antibodies prove effective in treating chronic conditions such as cancer and immunological disorders. As a dominant and well-established product class in protein therapeutics, monoclonal antibodies offer enhanced safety and immunogenicity compared to their counterparts. Cell-based expression systems, such as the Chinese hamster ovary (CHO) mammalian cell expression system, have addressed previous challenges associated with antibody drugs, leading to increased monoclonal antibody productivity. Over the past five years, the FDA has greenlit 213 drugs, with 44 being monoclonal antibodies, including twelve for the treatment of cancer and immunological disorders.

Major companies in the market are strategically introducing media systems to gain a competitive edge. Specifically designed for optimizing the production of therapeutic monoclonal antibodies, these media systems enhance efficiency in therapeutic protein manufacturing. For instance, Lonza Group AG, a Switzerland-based pharmaceutical manufacturing company, launched the TheraPRO CHO (Chinese Hamster Ovary) Media System in July 2023. This new cell culture platform simplifies media preparation with a chemically specified, two-part production technique, offering full scalability and support from technical professionals with extensive troubleshooting knowledge.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical company, acquired Protomer Technologies Inc. for $1 billion. This acquisition is seen as a valuable addition to Lilly's diabetes pipeline, leveraging Protomer's breakthrough technology. Protomer specializes in next-generation protein therapies utilizing its proprietary Molecular Engineering of Protein Sensors (MEPS) platform. Particularly, Protomer's glucose-sensing insulin program demonstrates promising potential in the field of diabetes treatment.

Major companies operating in the therapeutic proteins market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A, Bristol Myers Squibb Co., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring LLC, Chugai Pharmaceutical Co. Ltd., Biogen Inc., Kyowa Kirin Co. Ltd., Oramed Pharmaceuticals Inc., Sandoz International GmbH, Hualan Biological Engineering Inc., Genentech Inc., ProBiogen AG, Diasome Pharmaceuticals Inc., Generex Biotechnology Corp., GeneScience Pharmaceuticals Co. Ltd. North America was the largest region in the therapeutic proteins market in 2023. The regions covered in the therapeutic proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Within the therapeutic proteins market, the primary product categories include insulin, fusion proteins, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. Insulin, a peptide hormone produced by pancreatic beta cells, functions as a key anabolic hormone in individuals. It plays a crucial role in influencing fat, carbohydrate, and protein metabolism by enhancing glucose uptake from the blood into fat, liver, and skeletal muscle cells. These therapeutic proteins serve various functions, including enzymatic and regulatory activities, specialized targeting activities, vaccines, and protein diagnostics. They find applications in treating a wide range of conditions such as metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, among others.

The therapeutic proteins market research report is one of a series of new reports that provides therapeutic proteins market statistics, including industry global market size, regional shares, competitors with a therapeutic proteins market share, detailed therapeutic proteins market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic proteins industry. The therapeutic proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The countries covered in the therapeutic proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic proteins market consists of sales of antibody-based drugs, FC fusion proteins, and anticoagulants. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.